ArticleJournal of clinical & cellular immunology2016
Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update.
Christopher DeRenzo, Stephen Gottschalk
Open access · greenAbstract read
In one paragraphArticle in Journal of clinical & cellular immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
2 authors at 1 institution in 1 country.
Christopher DeRenzoCenter for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, Texas 77030, USA; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas 77030, USA; Department of Pediatrics Baylor College of Medicine, Houston, Texas 77030, USA.
Stephen GottschalkCenter for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, Texas 77030, USA; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas 77030, USA; Department of Pediatrics Baylor College of Medicine, Houston, Texas 77030, USA; Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas 77030, USA.
Texas Children's Hospital · US
Funding
VECTOR PRODUCTIONP01CA094237 · NCI · BAYLOR COLLEGE OF MEDICINE · PI HESLOP, HELEN E, ROONEY, CLIONA M. · 2002 to 2017
$27.8MPEDIATRIC ONCOLOGY CLINICAL RESEARCH TRAINING PROGRAMK12CA090433 · NCI · BAYLOR COLLEGE OF MEDICINE · PI CARL E ALLEN, Donald W. Parsons · 2002 to 2026
$18.5MReprogramming of T cells for the Treatment of MelanomaR01CA173750 · NCI · DANA-FARBER CANCER INST · PI GOTTSCHALK, STEPHEN, WUCHERPFENNIG, KAI W · 2012 to 2016
$5.0MCancer and Stroma-Targeted Immunotherapy with a Gentically Modified DC VaccineR01CA148748 · NCI · BAYLOR COLLEGE OF MEDICINE · PI GOTTSCHALK, STEPHEN, SONG, XIAOTONG · 2011 to 2015
$1.6MNCI NIH HHS K12 CA090433NCI NIH HHS P01 CA094237NCI NIH HHS R01 CA148748NCI NIH HHS R01 CA173750
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Cancer immunotherapyChimeric antigen receptorsGene therapyOsteosarcomaPediatric cancerT-cell therapyTumor antigens
Identifiers
PMID27313973
PMCPMC4904842
OpenAlexW2474905392
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390